The objective of this study was to develop an HER2-targeted, envelope-modified Moloney murine leukemia virus (MoMLV)-based gammaretroviral vector carrying interleukin (IL)-12 gene for bladder cancer therapy. It displayed a chimeric envelope protein containing a single-chain variable fragment (scFv) antibody to the HER2 receptor and carried the mouse IL-12 gene. The fragment of anti-erbB2scFv was constructed into the proline-rich region of the viral envelope of the packaging vector lacking a transmembrane subunit of the carboxyl terminal region of surface subunit. As compared with envelope-unmodified gammaretroviruses, envelopemodified ones had extended viral tropism to human HER2-expressing bladder cancer cell lines, induced apoptosis, and affected cell cycle progression despite lower viral titers. Moreover, animal studies showed that envelope-modified gammaretroviruses carrying IL-12 gene exerted higher antitumor activity in terms of retarding tumor growth and prolonging the survival of tumor-bearing mice than unmodified ones, which were associated with enhanced tumor cell apoptosis as well as increased intratumoral levels of IL-12, interferon-g, IL-1b, and tumor necrosis factor-a proteins. Therefore, the antitumor activity of gammaretroviruses carrying the IL-12 gene was enhanced through genetic modification of the envelope targeting HER2 receptor, which may be a promising strategy for bladder cancer therapy.
Introduction
The human epidermal growth factor receptor (EGFR) family is involved in signal transduction pathways resulting in cell proliferation, cell survival, angiogenesis, and metastasis in several human malignancies.
1 HER2 (one member of the EGFR family, also called erbB2) expression in urothelial cancers is variable, ranging from 8.5 to 81%, but it has a higher frequency in invasive bladder cancers. 2, 3 Some have reported a correlation between HER2 overexpression, a more aggressive clinical course 4, 5 and a poorer response to chemotherapy in bladder cancers. 6 Therefore, HER2-targeted strategies have become very good potential therapies for HER2-expressing bladder cancers. 7, 8 The minibody single-chain variable fragment (scFv), in which the antigen-binding domains of an antibody (V H and V L ) are joined by a flexible polypeptide linker, has considerable therapeutic potential against antigens involved in disease processes, and through the process of antigen-antibody binding, it has the ability to specifically target, 9 with or without blocking signal transduction. 10 De Lorenzo et al. 11 reported that anti-erbB2scFv not only induced internalization but also displayed an intrinsic, strong, and specific anti-proliferative activity toward HER2-expressing cells. With such characteristics, the minibody has a promising potential for targeted cancer therapy. In contrast, Neve et al. 12 showed that some antierbB2scFvs exhibited only ErbB2-mediated endocytosis, without any correlation with the cell cycle, cell proliferation, or intracellular kinase signal induction by internalizing antibodies.
Several investigators have used a modified viral envelope to enhance the specificity of infection by a chimera envelope to certain receptors, such as EGFR, 13 cMET, 14 and CEA. 15 They constructed a new plasmid carrying the envelope sequence with insertion of scFv cDNA into the gp70 of Moloney murine leukemia virus (MoMLV), such as the N-terminal receptor-binding domain (RBD) or the proline-rich region (PRR). Such a strategy can exert an ability to specifically target recombinant gammaretroviruses to certain receptors and then extend the gammaretroviral tropism. Despite this, the therapeutic performance still relies on an efficient transfer and expression of the gene of interest, which might influence cell survival or proliferation. 15 Interleukin (IL)-12 has a unique 70-kDa-heterodimeric structure composed of two covalently linked p35 and p40 subunits, both of which are required for biological activity. 16 IL-12 exhibits many biological effects, including a stimulatory effect on natural killer (NK) cells, the induction of cytotoxic T-cell activation, and the induction of interferon (IFN)-g production, 17, 18 and possesses antitumor, antiangiogenic, and antimetastatic activities. [19] [20] [21] IL-12 also has synergistic efficacy as an adjuvant for vaccination against cancers 22, 23 and can enhance HER2-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells with HER2 antigen presentation. 24 Therefore, this study was designed to investigate a new therapeutic strategy for HER2-expressing bladder cancer with envelope-modified gammaretroviruses displaying a scFv-targeted HER2 receptor and carrying the mouse IL-12 (mIL-12) gene. The synergistic effect of both minibody-tumor antigen binding and IL-12 expression was able to achieve an excellent therapeutic response in an immunocompetent syngeneic murine bladder tumor model.
Materials and methods
Cell lines, culture conditions, and mice Murine fibroblasts (NIH3T3) and bladder cancer cell line (MBT2), as well as human embryonic kidney cell line (293 cells) and bladder cancer cell lines (TSGH8301, J82, T24, and TCCSUP) were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM Lglutamine, and 50 mg/ml gentamicin. The cell cultures were maintained at 37 1C in a humidified atmosphere with 5% CO 2 . Female C 3 H/HeN mice at the age of 6-8 weeks were obtained from the Laboratory Animal Center of National Cheng Kung University Medical College and maintained under isothermal conditions with regular photo periods. All the animal studies were performed following the guidelines approved by the Laboratory Animal Care and Use Committee of the National Cheng Kung University.
Plasmid construction
The pCL-Eco-DTM plasmid was derived from the original pCL-Eco plasmid (Imgenex, San Diego, CA) in which 1-bp deletion at the 411-amino-acid site of the carboxyl terminal domain of the surface glycoprotein (SU) of the MoMLV envelope resulted in a frame-shift mutation at the initial portion of the transmembrane (TM) subunit. The coding region of anti-erbB2scFv was excised from the eukaryotic expression vector pMFverB 9 and inserted into the PRR of the envelope sequence of pCL-Eco-DTM plasmid through the pMECA plasmid, 7 to generate pCL-Eco-anti-erbB2scFv (designated as pCLEcoscFv). Furthermore, in frame fusion of the construct was verified by sequencing ( Figure 1 ). The coding regions of p35 and p40 subunits of IL-12 were obtained by PCR using adenoviral vector carrying mIL-12 (AdmIL-12, a kind gift from FL Graham 25 ) as the template. The sequence of internal ribosome entry site (IRES) of encephalomyocarditis virus (B600 bp) was also generated by PCR using pTCY-IRES-TK plasmid 7 as the template, in which the IRES sequence was originally derived from pIRES-hrGFP-1a (Stratagene, La Jolla, CA). The PCR primers were 5 0 -GGAATTCTTAGGCGGAGCTCAGA TAGC-3 0 (forward), 5 0 -TTCGCCTCGAGTCTATCGCT ACCTC-3 0 (reverse) for IL-12 p35, 5 0 -CGAGCTCATGT GTCCTCAGAAGCTAAC-3 0 (forward) and 5 0 -GCGTC GACTTAGGATCGGACCCTGCAG-3 0 (reverse) for Figure 1 Schematic illustrations of the plasmid constructs. The coding region of the anti-erbB2scFv was inserted into retroviral packaging vector pCL-Eco-DTM that lacked the transmembrane subunit of the envelope to generate pCL-EcoscFv. The p35 and p40 subunits of IL-12 as well as the sequence of the IRES were cloned into retroviral expression vector pCLNRX to yield pCL-IL12. The pCL-LacZ and pCL-Eco plasmids served as the controls. pCLMFGLacZ, pCLNRX, and pCL-Eco were from the Moloney murine leukemia virus (MoMLV)-based pCL Vector System (RetroMax System, Imgenex 
Generation of recombinant gammaretroviruses
To generate recombinant gammaretroviruses, 20 mg of the packaging vector and 20 mg of the expression vector were cotransfected into the 293 cells with the calcium phosphate precipitation method, according to the manufacturer's protocol. 26 These viruses were designated as Eco-LacZ, EcoscFv-LacZ, Eco-IL12, and EcoscFv-IL12, respectively. The virus-containing supernatants were harvested, filtered through 0.45-mm filters, and used directly for various experiments or stored at À80 1C until needed.
Determination of viral titers NIH3T3 cells were plated at a density of 1 Â 10 4 per well in 24-well plates for overnight culture and were infected with four 10-fold dilutions of stored virus-containing supernatants in the presence of 8 mg/ml of polybrene for at least 12 h, following the manufacturer's instruction. For recombinant gammaretroviruses that carried the b-galactosidase gene, the cells were stained with X-gal and the positive blue color-stained cells were calculated for determination of the viral titer 48 h after viral infection. As for gammaretroviruses carrying the IL-12 gene, G418-resistant colonies (750 mg/ml) of infected NIH3T3 cells were counted and expressed as colony-forming units (CFU) per milliliter, as described earlier. 27 Detection of gp70-anti-erbB2scFv chimera protein To detect the presence of gp70-anti-erbB2scFv chimera protein in the viral supernatants, a modified enzymelinked immunosorbent assay (ELISA) was performed. In brief, diluted mouse ascites (1:180) containing monoclonal antibody against MoMLV envelope gp70 (ATCC, CRL-1913) or p15E (ATCC, CRL-1893) protein, or against prothymosin a (1D10) serving as a negative control was immobilized on 96-well ELISA plates at 4 1C overnight. The plates were then washed three times with washing buffer (0.05% Tween-20/PBS) and blocked with blocking buffer (1% BSA/PBS) for 2 h. The 100 ml per well of the viral supernatant were incubated overnight at 4 1C. After washing, the plate was subsequently incubated for 2 h with recombinant HER2-Fc chimera protein (extracellular domain, 1129-ER, R&D Systems, Minneapolis, MN) at a concentration of 2 mg/ml at room temperature, followed by addition of biotin-conjugated goat anti-human Fc (1:5000, R&D Systems) for another 2 h and streptavidin-peroxidase (KPL, Gaithersburg, MD) for 20 min, and then reacted with 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma, St Louis, MO). The optical density was immediately determined by using an ELISA reader set to 450 nm, with a wavelength correction at 570 nm.
Cytotoxicity assay
Cells were plated at a density of 1 Â 10 3 per well in 96-well plates for overnight culture and infected with gammaretroviruses carrying the LacZ gene (Eco-LacZ or EcoscFvLacZ) at a multiplicity of infection (MOI) of 1. When the control wells were near 80-90% confluence, cell viability using an MTT assay was performed. MTT solution (1 mg/ml, 100 ml) was added to each well for 4 h at 37 1C to allow MTT to form formazan crystals by reacting with metabolically active cells. After the incubation was completed, the supernatants were removed. Dimethyl sulfoxide (100 ml) was added, and transferred to another 96-well plate. The optical density of each well was determined using an ELISA reader set to 570 nm. The percentage of cell growth was calculated by comparing the absorbance reading from the treated vs the control cells.
Cell cycle analysis MBT2 cells were seeded in 10-cm plates at a density of 1 Â 10 5 per plate and infected with gammaretroviruses as indicated at an MOI of 0.25 or 1. After 2 days, cells were detached, washed with PBS, and resuspended in PI staining buffer (50 mg/ml propidium iodide, 0.1% NP-40, 10 mg/ml RNase A). After 30 min of incubation at room temperature, cell cycle analysis was performed on a FACS Calibur Flow Cytometer (Becton Dickinson, San Jose, CA). The percentage of cells in each phase of the cell cycle (G1, S, and G2/M) was calculated by using Modfit software (Becton Dickinson), and compared with the results obtained with control untreated cells.
Detection of apoptosis
To test apoptotic death, MBT2 cells were seeded in 10-cm plates at a density of 1 Â 10 5 per plate in the absence or presence of recombinant gammaretroviruses, as indicated (each at an MOI of 1). After 2 days, cells were harvested, washed in PBS, and treated with Annexin V-FITC after resuspension in binding buffer according to the manufacturer's instruction (Annexin V-FITC Apoptosis Detection kit, Strong Biotech. Corp., Taipei, Taiwan). Labeled cells were analyzed using the FACS Calibur flow cytometer (Becton Dickinson); the data were processed using Cell Quest software (Becton Dickinson).
Measurement of IL-12 and IFN-g by ELISA
The levels of IL-12 and IFN-g were determined by commercial ELISA kits (R&D Systems) according to the manufacturer's instruction. The biological activity of IL-12 was determined by the induction of IFN-g production. In brief, mouse splenocytes were harvested from three C3H/HeN mice, and 2 Â 10 6 splenocytes were seeded in 24-well plates with Con A (2 mg/ml). IL-12-containing supernatants as indicated were added. After 72 h, supernatants were collected for the measurement of IFN-g by ELISA.
Enhanced killing of HER2-positive tumors by gammaretrovirus Y-S Tsai et al Animal studies MBT2 cells (2 Â 10 6 cells in 100 ml PBS) were injected subcutaneously into the flanks of 6-to 8-week-old C3H/ HeN mice on day 0. On day 8, when visible and palpable nodules developed, the mice with 10-11 mice per group were injected intratumorally with various recombinant gammaretroviruses (5 Â 10 3 CFU/dose) or with control medium for 8 consecutive days. Tumor volume and mouse survival were recorded every 2 days according to the 'Guidelines for the Welfare of Animals in Experimental Neoplasia' (1998) during the 60-day experimental period. Tumor volumes were calculated using the formula: (length of tumor) Â (width of tumor) 2 Â 0.45. The mean tumor volume was calculated while all the mice in the same treatment group were still alive.
Determination of apoptotic cell number
Typical apoptotic cell death in tumors, presenting as cell shrinkage, with condensed hyperchromatic nuclear chromatin and deeply eosinophilic cytoplasm surrounded by a clear 'halo', occurs in a well-vascularized area full of proliferating tumor cells, some of which appear as mitotic figures. Tumor specimens obtained from three tumorbearing mice 5 days after five viral injections were harvested and embedded for hematoxylin and eosin staining. Microscopically, the number of apoptotic cells was calculated and averaged from every five high-power fields.
Assessment of intratumoral levels of IL-12, IFN-g, IL-1b, and tumor necrosis factor-a For detection of intratumoral levels of cytokines, MBT2 tumor-bearing mice that had been treated with various recombinant gammaretroviruses as described above for 5 consecutive days starting on day 8 were killed on day 17. A portion of tumor specimens were obtained and used to prepare total tumor cell lysates for the determination of levels of IL-12, IFN-g, IL-1b, and tumor necrosis factor (TNF)-a proteins using ELISA kits (R&D Systems) according to the manufacturer's instruction. Data were presented after normalization with the tumor protein level.
Statistical analysis
Experimental results were analyzed for statistical significance (Student's t-test) or curve-fit analysis using Prism GraphPad Prism 4.00 for Windows (GraphPad Software, San Diego, CA) and SigmaPlot 8.0 (SPSS Inc., Chicago, IL) software packages. The difference in the mean relative tumor size ± s.e.m. was examined using analyses of covariance with days as the covariate using SPSS software (SPSS 12.0 for Windows, SPSS Inc.). Results presented are representative of at least duplicate experiments, and statistical significance is indicated (*Po0.05; **Po0.01; ***Po0.001).
Results
Determination of viral titers NIH3T3 cells, 1 Â 10 5 cells per well seeded in a 24-well plate overnight, were infected with serial 10-fold dilutions of Eco-LacZ or EcoscFv-LacZ gammaretroviruses. X-gal staining was done and the positive blue color-stained cells were counted. The viral titers were about 1.1 Â 10 5 CFU/ ml for envelope-unmodified gammaretroviruses (EcoLacZ) and 1.7 Â 10 4 CFU/ml for envelope-modified gammaretroviruses (EcoscFv-LacZ).
Detection of gp70-anti-erbB2scFv chimera protein Using a modified ELISA with anti-gp70 as the capture antibody, we showed that envelope-modified viral supernatant contained gp70-anti-erbB2scFv chimera proteins, as revealed by higher absorbance compared with unmodified viral supernatant or the control soluble antierbB2 scFv protein (Figure 2 ). When monoclonal antibody against p15E (a TM subunit of the envelope) or prothymosin a (an unrelated protein serving as a negative control) was used as the capture antibody in the assay, all samples had negligible absorbance. Furthermore, when no capture antibody was applied to the plates, all the samples bound to the solid phase with various degrees, as revealed by different absorbance. Taken together, these results indicate that the modified ELISA using anti-gp70 as the capture antibody was specific for detection of gp70-anti-erbB2scFV and the EcoscFv-LacZ viral supernatant contained gp70-anti-erbB2ScFv chimera protein.
Infectivity and killing of HER2-expressing human bladder cancer cells
To assess the infectivity and cytotoxic activity of the envelope-unmodified and -modified recombinant gammaretroviruses (Eco-LacZ and EcoscFv-LacZ), we infected several HER2-expressing bladder cancer cells for at least 12 h at an MOI of 1. The relative infectivity results showed that the envelope-modified gammaretroviruses EcoscFv-LacZ had a 10-to 1000-fold greater increase than the envelope-unmodified gammaretroviruses Eco-LacZ in HER2-expressing bladder cancer cells (Figures 3a and b) . As for the effect on cell survival, EcoscFv-LacZ gammaretrovirus infection caused a 5-14% death rate among HER2-expressing tumor cells 2 days after infection. In contrast, in Eco-LacZ gammaretrovirus infections, about 98-100% of HER2-expressing tumor cells survived (Figure 3c ).
Induction of apoptosis of MBT2 cells infected with EcoscFv-LacZ gammaretrovirus
To determine whether the mechanism of cell death occurred after infection with EcoscFv-LacZ, we used annexin V to measure the appearance of phosphatidylserine, a marker of apoptosis, on the outer leaflet of the plasma membrane of MBT2 cells. Cells treated with EcoscFv-LacZ gammaretroviruses were found to bind more FITC-conjugated annexin V than untreated cells or cells treated with Eco-LacZ gammaretroviruses (Figure 4a ). These results showed that the nature of cell death in EcoscFv-LacZ infection was apoptotic.
Effects of EcoscFv-LacZ gammaretroviruses on cell cycle of MBT2 cells
To test whether a growth arrest contributed to the antitumor action of EcoscFv-LacZ, MBT2 cells were infected with Eco-LacZ or EcoscFv-LacZ for at least 12 h at 37 1C. Two days later, cell cycle analysis by flow cytometry was performed. EcoscFv-LacZ significantly reduced the percentage of MBT2 cells entering the G2/M phase and produced an accumulation of cells in the G0/G1 phase (Figure 4b ).
Detection of IL-12 protein secreted from cells infected with recombinant gammaretroviruses carrying the IL-12 gene
To demonstrate the expression and secretion of IL-12 protein in NIH3T3 cells infected with recombinant gammaretroviruses carrying the IL-12 gene, the supernatants from virus-producing 293 cells, G418-resistant NIH3H3 cells infected with Eco-IL12 or EcoscFv-IL12, as well as NIH3H3 cells infected with Eco-LacZ or EcoscFv-LacZ were obtained and assessed for their IL-12 contents by ELISA. As expected, the amount of IL-12 was B1900 pg/ml in the supernatants from pCL-IL12-transfected, Eco-IL12-and EcoscFv-IL12-producing 293 cells, but the IL-12 amount was undetectable in the others. The amount of IL-12 in the supernatant collected from G418-resistant NIH3T3 cells that had been infected with Eco-IL12 or EcoscFv-IL12 was B2200 pg/ml (Figure 5a ). 
Enhanced killing of HER2-positive tumors by gammaretrovirus Y-S Tsai et al
Induction of IFN-g production from Con A-primed splenocytes To determine whether the secreted IL-12 protein shown in Figure 5a exhibits biological activity, we performed an IFN-g induction assay. As shown in Figure 5b , addition of recombinant IL-12 enhanced the production of IFN-g by Con A-primed splenocytes. Increased IFN-g production was also noted in the supernatant of Con A-primed splenocytes in the presence of the conditioned medium obtained from EcoscFv-IL12-infected NIH3T3 cells, as compared with that from EcoscFv-LacZ-infected cells (Figure 5b ). 
In vivo antitumor activity

Increased number of apoptotic cells
After staining and counting, there was significantly more apoptotic cells in tumors treated with envelope-modified gammaretroviruses (EcoscFv-LacZ and EcoscFv-IL12) than those treated with unmodified ones (Eco-LacZ and Eco-IL12) or the control (Figures 7a and b) .
Increased cytokine levels in tumors treated with EcoscFv-IL12 gammaretrovirus
The results from the ELISA showed that IL-12 levels were higher in tumors treated with Eco-IL12 or EcoscFv-IL12, but were undetectable in those treated with Eco-LacZ or the control. A relatively lower IL-12 level could be detected within the tumor treated with EcoscFv-LacZ (Figure 8a) . Similarly, the levels of IFN-g were significantly higher in the tumors treated with Eco-IL12 or EcoscFv-IL12 than those treated with Eco-LacZ, EcoscFv-LacZ, or the control (Figure 8b ). On the other hand, the levels of both IL-1b and TNF-a were significantly higher in the tumors treated with EcoscFv-IL12 than those in the remaining four groups (Figures 8c  and d ).
Discussion
In this study, we altered the tropism of the gammaretroviral vector to infect HER2-expressing human bladder cancer cells through the recognition of the HER2 molecule on the tumor cell surface, and the IL-12 protein can be expressed after infection. In contrast with wildtype MoMLV, the anti-erbB2scFv-modified MoMLV carrying reporter genes can extend their tropism to several HER2-expressing human bladder cancer cell lines. Moreover, such gammaretroviruses can induce tumor cell apoptosis and influence the cell cycle. With a synergistic effect from IL-12 protein and the binding process of the HER2 receptor-anti-erbB2scFv minibody, the antitumor activity was enhanced and the survival of the mice was prolonged, which were associated with increased apoptosis, IL-12, IFN-g, IL-1b, and TNF-a within the tumors. The host range of gammaretroviruses is dependent on the SU, which recognizes and binds to a specific cell receptor protein. The ecotropic MoMLV recognizes receptors only on rodent cells, and rarely on human cells, and its host range is restricted to rodent cells. 26 One of the challenges in the engineering of gammaretroviral envelope proteins is to direct viruses to cell surface molecules expressed by tumor cells without impairing viral entrance. Several key steps have to be overcome: the modified envelope has to be functionally expressed in the packaging cells, the envelope has to become incorporated into the viral particles, the viral particles have to attach to the cell of choice, membrane fusion has to be triggered, and the gene of interest has to be expressed. Previous studies have shown that the generation of gammaretroviral vectors incorporated with a scFv antibody fused to envelope protein could be inserted close to the N terminus of the ecotropic MoMLV envelope protein, 15 or to the PRR of the surface glycoprotein that has been used to insert molecules of interest on amphotropic, but not ecotropic MoMLV. 14, 28 Generally, the success of infection should be aided by the presence of wide-type envelope (unmodified) protein; the ratio of wide-type and modified envelope protein in the viral particles appears to determine the efficiency of infection. The presence of large amounts of wide-type envelopes may inhibit binding of the modified envelope to its antigen on the cell surface. The existence of a modified envelope alone has been suggested to have too much affinity to initiate membrane fusion after conformational changes of receptor binding. 29 For example, amphotropic gammaretroviral envelope glycoproteins that display EGF cannot infect human cells that express both EGF receptors and amphotropic receptors. 30, 31 Inhibition of infectivity is specifically caused by interaction with the high affinity EGF receptor, as competition with soluble EGF can restore infectivity through the amphotropic receptor. Since the TM protein, but not the SU of the gammaretroviral envelope, is required for envelope fusion, 32 some mutations located within the TM region (TM-T25P, TM-L57V) and the presence of the R peptide of the TM subunit contributes to the inhibition of envelope fusion. In this study, despite the lack of TM protein, anti-erbB2scFv, In this study, only a 5-14% death rate of infected cells found in the MTT assay 2 days after viral infection may reflect lower viral titers. The inconsistencies between the results from the MTT assay and annexin V staining may result from the time process during the cell death. The former measures the mitochondrial activity during cell death, whereas the latter detects the appearance of phosphatidylserine in the initial phase of cell apoptosis. Therefore, detection of annexin V is more sensitive and rapid than the MTT assay in the aspect of cell death. On the other hand, although the methods of purification and concentration with polybrene and chrondoitin sulfate C were reported to be useful for amphotropic and ecotropic recombinant retroviruses, 33 no report discussed whether the concentration methods work well for envelopemodified recombinant gammaretroviruses that lack TM domain. As we were concerned that the concentration procedures may change the surface configuration of scFv, 34 resulting in affecting the antigen-binding ability, we did not use this procedure in this study.
In our studies, the anti-erbB2scFv-modified MMLV could infect HER2-expressing cancer cells without combining wild-type envelope. We also demonstrated that They not only induce internalization, but also display an intrinsic, strong, and specific anti-proliferative activity toward HER2-positive cells. 11 Moreover, a new antierbB2 antibody, Erb-hcAb, by fusing with a human antierbB2scFv selectively cytotoxic to erbB2-positive cells, and a human Fc domain, can induce apoptosis and inhibit cell cycle progression in erbB2-positive cells. 35 However, as shown in this study, cell death caused by modified gammaretroviruses was independent of HER2 expression, suggesting some HER2-expressing cells may or may not be dependent on p185-mediated mitogenic signaling and have some cross-talk signaling. 36 Several studies showed that IL-12 is an important cytokine for ex vivo recovery and maintenance of HER2 antigen-specific CD4 þ T lymphocytes that might be lost by using IL-2 alone in combination with antigen. 24, 37 Moreover, an anti-erbB2 antibody-IL-12 chimeric protein exerts an antitumor activity, and the mechanism involves a combination of T and NK cell activity, a switch to a Th1 immune response, and antiangiogenic activity. 38 The results from the current animal studies showed that treatment with envelope-modified gammaretrovirus targeting the HER2 receptor carrying the LacZ gene exerts a weak antitumor activity. When carrying the IL-12 gene, the efficacy of antitumor activity was enhanced, initially suggesting the synergistic effect derived from the binding of the HER2 antigen and anti-erbB2scFv and IL-12 protein. Further analyses from the tumor specimen demonstrated that therapies with envelope-modified gammaretroviruses can induce more tumor cell apoptosis. As apoptotic cell debris may be removed and recognized by macrophage, it may cause macrophage phenotype shift and decrease the production of TNF-a and IL-12 proteins. 39 Despite this, it was reported that exogenous IL-12 can potently activate macrophages during intracellular infection, such as mycobacteria, and this activating effect through TNF-a release is mediated primarily through its effect on the release of IFN-g by macrophages. 40 Like this, such an antitumor activity in this study might be enhanced through IL-12 and IL-12-mediated IFN-g production.
In conclusion, our results show that production of antierbB2scFv-modified MoMLV is independent of the wildtype envelope combination. In addition, the modified gammaretroviruses exerted antitumor activity through targeting and binding of anti-erbB2scFv to HER2 receptor on bladder cancer cells. When this modified gammaretrovirus expresses the IL-12 gene, it demonstrates a better therapeutic efficacy compared with that of the unmodified one, which is associated with increased production of TNF-a and IL-1b. Such an anti-erbB2scFv-modified MoMLV carrying the IL-12 gene may be a promising strategy for HER2-positive bladder cancer therapy.
